<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
RIBOZYME PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $.01
(Title of Class of Securities)
762567105
(CUSIP Number)
ELAN INTERNATIONAL SERVICES, LTD.
c/o Brock Silverstein LLC
800 Third Avenue, 21st floor
New York, New York 10022
(212) 371-2000
Attention: David Robbins, Esq.
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
January 7, 2000
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /
(Continued on the following pages)
<PAGE>
- ------------------------------- -------------------------------
CUSIP No. 762567105 13D Page 2
- ------------------------------- -------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON Elan International Services, Ltd.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS WC
- --------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) OR 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda
- --------------------------------------------------------------------------------
Number of 7 SOLE VOTING POWER 1,141,026
Shares
(See Item 5)
-------------------------------------------------------------
Beneficially 8 SHARED VOTING POWER 0
Owned by
-------------------------------------------------------------
Each Reporting 9 SOLE DISPOSITIVE POWER 1,141,026
(See Item 5)
-------------------------------------------------------------
Person With 10 SHARED DISPOSITIVE POWER 0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,141,026 shares (See Item 5)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.22% (based on 11,234,135 shares outstanding as set forth in the
Issuer's quarterly report on Form 10-Q for the quarter ended September
30, 1999)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON CO
- --------------------------------------------------------------------------------
<PAGE>
- ------------------------------- -------------------------------
CUSIP No. 762567105 13D Page 3
- ------------------------------- -------------------------------
ITEM 1. SECURITY AND ISSUER.
Common Stock, par value $0.01 per share (the "Common Stock"), of
Ribozyme Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"). The
principal executive offices of the Issuer are located at 2950 Wilderness Place,
Boulder, Colorado 80301.
ITEM 2. IDENTITY AND BACKGROUND.
This Form 13-D is filed by Elan International Services, Ltd.,
a Bermuda exempted company ("EIS"), 102 St. James Court, Flatts, Smiths Parish,
FL 04, Bermuda. EIS is a wholly-owned subsidiary of Elan Corporation, plc, an
Irish public limited company ("Elan"), with its principal offices located at
Lincoln House, Lincoln Place, Dublin 2, Ireland. During the last five years,
none of the directors or officers of EIS: (i) have been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors); or (ii) was a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction, as a result of which proceeding it was or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, United States federal or state securities
laws, or finding any violation with respect to such laws.
ITEM 3 SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
On January 7, 2000, pursuant to a Securities Purchase Agreement, dated
January 7, 2000, by and between EIS and the Issuer, EIS acquired (a) 641,026
shares of Common Stock of the Issuer, (b) a warrant to acquire up to 200,000
shares of Common Stock at an exercise price of $15.00 per share (the "A
Warrant"), (c) a warrant to acquire up to 300,000 shares of Common Stock at an
exercise price of $20.00 per share (the "B Warrant"; together with the A
Warrant, the "Warrants"), and (d) 12,015 shares Series A Preferred Stock, par
value $.01 per share, of the Issuer, for aggregate consideration of $17,015,000.
The consideration for the above-referenced securities was provided by EIS's
general corporate funds. In addition, the Issuer issued to EIS a convertible
promissory note in an aggregate principal amount of $12,015,000 (the
"Convertible Note"), which bears interest at an annual rate of 12%. Pursuant to
the Securities Purchase Agreement, and subject to certain conditions contained
therein, EIS shall purchase Common Stock valued at $5,000,000.
As long as EIS or its affiliates, directly or indirectly, collectively
own at least 10% of the Issuer's Common Stock or its affiliates (or securities
convertible, exchangeable or exercisable for or into Common Stock which with
such Common Stock represents at least such 10% ownership, assuming conversion
thereof but not of any other such Common Stock equivalents) or until the date
that is five years after the date hereof, EIS shall be entitled to nominate one
member to the Issuer's Board of Directors.
The shares of Series A Preferred Stock held by EIS are not convertible
into shares of Common Stock until January 7, 2002. The Warrants are convertible
into 500,000 shares of Common Stock at the option of EIS. As of January 7, 2000,
the Convertible Note is not convertible into any shares of Common Stock.
<PAGE>
- ------------------------------- -------------------------------
CUSIP No. 762567105 13D Page 4
- ------------------------------- -------------------------------
ITEM 4. PURPOSE OF TRANSACTION
EIS acquired the above-referenced securities for investment purposes.
Except as set forth above, EIS has no plan or proposal which relates to
or would result in:
(a) The acquisition by any person of additional securities of
the Issuer, or the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction such as a merger,
reorganization or liquidation involving the Issuer or any of its
subsidiaries;
(c) A sale or transfer of a material amount of assets of the
Issuer or any of its subsidiaries;
(d) Any change in the present Board of Directors or management
of the Issuer, including any plans or proposals to change the number of
or term of Directors or to fill any existing vacancies on the Board;
(e) Any material change in the present capitalization or
dividend policy of the Issuer;
(f) Any other material change in the Issuer's business or
corporate structure;
(g) Changes in the Issuer's charter, by-laws, or instruments
corresponding thereto or other actions which may impede the acquisition
of control of the Issuer by any person;
(h) Causing the Common Stock to cease to be authorized to be
traded on the Nasdaq National Market;
(i) To have the Common Stock terminated from registration
under the Securities Act of 1933; or
(j) Any action similar to any of those enumerated above.
<PAGE>
- ------------------------------- -------------------------------
CUSIP No. 762567105 13D Page 5
- ------------------------------- -------------------------------
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER.
With respect to EIS:
(a) 1,141,026 shares of Common Stock, representing 9.22%
(assuming conversion of the Warrants and based upon 11,234,135 shares of the
Common Stock outstanding pursuant to the Issuer's 10-Q filed with the Securities
and Exchange Commission on November 15, 1999).
(b) Sole power to vote: 1,141,026
Shares shared power to vote: -0-
Sole power to dispose: 1,141,026
Shares shared power to dispose: -0-
(c) None.
(d) None.
(e) Not Applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER.
Pursuant to the Convertible Note issued to the Issuer by EIS, the
Issuer may draw down up to $12,015,000 at any time after January 7, 2000. From
the date of issuance until the Note is paid in full, EIS shall have the right to
convert all or a portion of the outstanding principal amount, including any
unpaid interest thereon, into such number of the Issuer's Series B Preferred
Stock obtained by dividing the sum of the outstanding principal amount,
including any interest accrued thereon, by $1,000, subject to certain
adjustments.
In addition, in connection with the acquisition of the
above-referenced securities, the Issuer and EIS caused to be formed a joint
venture company, Medizyme Pharmaceuticals Ltd. ("Medizyme"), a Bermuda
corporation. Pursuant to the Series A Certificate of Designations, EIS may
exchange, at any time, all of the outstanding shares of Series A Preferred
Stock held by EIS into 50% of the then outstanding capital stock of Medizyme.
Except as described above, there are no contracts, arrangements,
understandings or relationships (legal or otherwise) among EIS or between such
persons and any other person with respect to any securities of the Issuer,
including but not limited to, transfer or voting of any securities of the
Company, finder's fees, loan or option arrangements, puts or calls, guarantees
of profits, divisions of profits or loss, or the giving or withholding of
proxies.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.
1. Securities Purchase Agreement, dated January 7, 2000.
<PAGE>
- ------------------------------- -------------------------------
CUSIP No. 762567105 13D Page 6
- ------------------------------- -------------------------------
SIGNATURE
After reasonable inquiry and to the best of its knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated as of: January 20, 2000
ELAN INTERNATIONAL SERVICES, LTD.
By: /s/ Kevin Insley
------------------------------
Name: Kevin Insley
Title: Director
<PAGE>
Exhibit 99.1
EXECUTION COPY
SECURITIES PURCHASE AGREEMENT
SECURITIES PURCHASE AGREEMENT (this "AGREEMENT"), dated as of
January 7th, 2000, among RIBOZYME PHARMACEUTICALS, INC., a Delaware corporation
(the "COMPANY"), and ELAN INTERNATIONAL SERVICES, LTD., a Bermuda exempted
limited liability company ("EIS"), and a wholly-owned subsidiary of ELAN
CORPORATION, PLC, an Irish public limited company ("ELAN").
R E C I T A L S:
A. The Company desires to issue and sell to EIS, and EIS
desires to purchase from the Company, (i) initially 12,015 shares of a
newly-created series of the Company's preferred stock, par value U.S.$.01 per
share, captioned "Series A Convertible Exchangeable Preferred Stock" (the
"SERIES A PREFERRED STOCK"), (ii) a warrant (as amended at any time, the "A
WARRANT") to purchase up to 200,000 shares of the Company's common stock, par
value U.S.$.01 per share (the "COMMON STOCK"), as provided therein, in the form
attached hereto as EXHIBIT A, and (iii) a warrant (as amended at any time, the
"B WARRANT"; together with the A Warrant, the "WARRANTS") to purchase up to
300,000 shares of Common Stock as provided therein, in the form attached hereto
as EXHIBIT B. The Company also desires to issue and sell to EIS, and EIS desires
to purchase from the Company, within 60 days of the date hereof 641,026 shares
of the Company's Common Stock. The Company also desires to issue and sell to
EIS, and EIS desires to purchase from the Company, a convertible promissory note
in the maximum outstanding principal amount of $12,015 million in the form
attached hereto as EXHIBIT C (the "NOTE"), which shall be exchangeable, as
provided herein, for initially up to 12,015 shares of a newly-created series of
the Company's preferred stock, par value U.S.$.01 per share, captioned "the
Series B Convertible Preferred Stock" (the "SERIES B PREFERRED STOCK"; together
with the Series A Preferred Stock and the Common Stock, the "SHARES"; and
together with the Warrants and the Note, the "SECURITIES"), which Securities
shall be issued to EIS pursuant to this Agreement, in accordance with its terms
and subject to the conditions contained herein. The rights, preferences and
privileges of the Series A Preferred Stock and, when issued, the Series B
Preferred Stock, are as set forth in the Certificate of Designations,
Preferences and Rights (the "CERTIFICATE OF DESIGNATIONS"), in the form attached
hereto as EXHIBIT D.
B. The Company and EIS have formed MEDIZYME PHARMACEUTICAL
LTD., an exempted limited liability company incorporated under the laws of
Bermuda ("NEWCO"), and pursuant to the terms of a Subscription, Joint
Development and Operating Agreement, dated as of the date hereof (as amended
at any time, the "JDOA"), simultaneously with the transactions contemplated
by this Agreement, (i) the Company shall acquire 6,000 voting common shares
of Newco, par value U.S.$1.00 per share (the "NEWCO COMMON SHARES"),
representing 100% of the issued and outstanding shares of such class of
stock, and 3,612 non-voting convertible preference shares of Newco, par value
of U.S.$1.00 (the "NEWCO PREFERRED SHARES"; together with the Newco Common
Shares, the "NEWCO SHARES"), representing 60.2% of the aggregate outstanding
Newco Preferred Shares and, on a fully diluted
<PAGE>
basis, 30.1% of the aggregate outstanding Newco Shares, and (ii) EIS shall
acquire 2,388 Newco Preferred Shares, representing [Deleted] of the aggregate
outstanding Newco Preferred Shares, and, on a fully diluted basis, 39.8% of
the Newco Shares. Additionally, as of the date hereof, Newco has entered into
license agreements with (i) Elan and its subsidiary Elan Pharma International
Limited (such agreements, as amended at any time, collectively, the "ELAN
LICENSE AGREEMENT"), and (ii) the Company (such agreement, as amended at any
time, the "COMPANY LICENSE AGREEMENT"; together with the Elan License
Agreement, the "LICENSE AGREEMENTS").
C. The Company and EIS are executing and delivering on the
date hereof a Registration Rights Agreement, in the form attached hereto as
EXHIBIT E (as amended at any time, the "COMPANY REGISTRATION RIGHTS AGREEMENT"),
in respect of (i) the Common Stock issued or issuable upon conversion of the
Series A Preferred Stock or Series B Preferred Stock or exercise of all or any
portion of the Warrants and/or (ii) the Common Stock being issued and purchased
hereunder, and any other Common Stock issued to EIS or any of its affiliates or
permitted transferees upon any stock split, stock dividend, recapitalization or
similar event affecting the Securities. The Company, EIS and Newco are also
executing and delivering on the date hereof a Registration Rights Agreement in
the form attached hereto as EXHIBIT F (as amended at any time, the "NEWCO
REGISTRATION RIGHTS AGREEMENT"). Additionally, the Company and EIS are executing
and delivering on the date hereof a Funding Agreement in the form attached
hereto as EXHIBIT G (the "FUNDING AGREEMENT"; together with this Agreement, the
Certificate of Designations, the JDOA, the Company Registration Rights
Agreement, the Newco Registration Rights Agreement, the License Agreements and
each other document or instrument executed and delivered in connection with the
transactions contemplated hereby and by the JDOA, the "TRANSACTION DOCUMENTS").
A G R E E M E N T:
The parties hereto agree as follows:
SECTION 1. CLOSING.
(a) TIME AND PLACE. The closings of the transactions
contemplated hereby shall occur (i) on the date hereof (the "INITIAL CLOSING;
the date thereof, the "INITIAL CLOSING DATE"), (ii) on the date that is 60 days
after the date hereof (the "STOCK PURCHASE CLOSING"; the date thereof, the
"STOCK PURCHASE CLOSING DATE") and (iii) the date that is 15 months after the
date hereof (the "SUBSEQUENT CLOSING"; the date thereof, the "SUBSEQUENT CLOSING
DATE"; together with the Initial Closing Date and the Stock Purchase Closing
Date, a "CLOSING DATE"), in each case at the offices of Brock Silverstein LLC,
800 Third Avenue, 21st Floor, New York, New York 10022.
(b) ISSUANCE OF SECURITIES. At the Initial Closing, subject to
the terms and conditions hereof, the Company shall issue and sell to EIS, and
EIS shall purchase from the Company: (i) 12,015 shares of Series A Preferred
Stock and (ii) the Warrants. At the Stock Purchase Closing, subject to the terms
and conditions hereof, the Company shall issue and sell to EIS, and EIS shall
purchase from the Company, 641,026 shares of Common Stock. At the Subsequent
Closing, subject to the terms and conditions hereof, the Company shall issue and
sell to EIS, and EIS shall purchase from the Company a number of shares of
Common Stock set forth below.
2
<PAGE>
(c) PURCHASE PRICE. The purchase price for (i) the 12,015
shares Series A Preferred Stock and the Warrants shall be U.S.$12,015,000 (the
"INITIAL PURCHASE PRICE"), (ii) the 641,026 shares of Common Stock shall be
$5,000,000 (the "COMMON STOCK PURCHASE PRICE") and (iii) the shares of Common
Stock at the Subsequent Closing shall be $5,000,000 (the "SUBSEQUENT PURCHASE
PRICE"; together with Initial Purchase Price and the Common Stock Purchase
Price, the "PURCHASE PRICE").
(d) INITIAL CLOSING DELIVERY. On the Initial Closing Date,
subject to the terms and conditions hereof and applicable regulatory approvals,
(i) EIS shall pay the Initial Purchase Price by wire transfer to an account
designated by the Company, (ii) the parties hereto shall execute and deliver to
each other, as applicable: (A) certificates for the Series A Preferred Stock;
(B) the Warrants; (C) the Company Registration Rights Agreement; (D) the Newco
Registration Rights Agreement; (E) the JDOA; (F) the Certificate of
Designations, as filed with the Secretary of State of the State of Delaware; (G)
the License Agreements; (H) the Funding Agreement; (I) certificates as to the
incumbency of the officers of the Company executing any of the Transaction
Documents; and (J) any other documents or instruments reasonably requested by a
party hereto and (iii) the Company shall cause to be delivered to EIS an opinion
of counsel in the form attached hereto as EXHIBIT H.
(e) COMMON STOCK CLOSING DELIVERY. On the Stock Purchase
Closing Date, subject to the terms and conditions hereof and applicable
regulatory approvals, EIS shall pay the Common Stock Purchase Price by wire
transfer to an account designated by the Company and the Company shall execute
and deliver to EIS: (A) certificates for the Common Stock and (B) any other
documents or instruments reasonably requested by EIS, including updates of the
documents referred to in clauses 1(d)(ii)(I) and 1(d)(iii) above as well as a
certification that the representations in Section 2 hereof are, as of such date,
true and correct in all material respects.
(f) SUBSEQUENT CLOSING DELIVERY. On the Subsequent Closing
Date, subject to the terms and conditions hereof, the Company shall issue and
sell to EIS, and EIS shall purchase from the Company additional shares of Common
Stock, in accordance with the following terms and conditions:
(i) The purchase price per share shall be a price
equal to [Deleted] over the Market Price Per Share of such Common
Stock. The Market Price Per Share shall be the average closing price
for the 45 trading days preceding the day that is two business days
prior to the Subsequent Closing Date. If Newco shall have determined
not to file and investigational new drug application (an "IND") with
the U.S. Food and Drug Administration in respect of a compound or
compounds mutually reasonably determined by EIS and the Company or no
such determination shall have been made by the Subsequent Closing Date,
then, in such event, the Purchase Price Per Share shall be recalculated
to reduce the premium of the Market Price Per Share of such Common
Stock by 5% for each full calendar month following the Subsequent
Closing Date that an affirmative determination to file an IND shall not
have been made (as reasonably determined by Newco upon the reasonable
and good faith agreement of Newco's management committee or, failing
such agreement, agreement of senior management of each of RPI and
Elan); provided, that such premium to the Market Price Per Share shall
3
<PAGE>
not be reduced below zero. If the purchase price is so adjusted,
additional shares of Common Stock shall be issued to EIS within 10
business days of the earlier of (x) the date of such affirmative
determination to file an IND, as described above, and (y) the date that
is six months after the Subsequent Closing Date to reflect such
adjustment;
(ii) EIS shall pay the Subsequent Purchase Price by
wire transfer to an account designated by the Company; and
(iii) The Company shall deliver to EIS (A) a
certificate or certificates representing such Common Stock and (B) any
other documents or instruments reasonably requested by EIS, including
updates of the documents referred to in clauses 1(d)(ii)(I) and
1(d)(iii) above as well as a certification that the representations in
Section 2 hereof are, as of such date, true and correct in all material
respects.
(g) NOTE AND SERIES B PREFERRED STOCK. The Company shall issue
and sell to EIS, and EIS shall purchase from the Company, the Note. Drawdowns
thereunder shall be made as provided in the Note, upon at least 10 days' written
notice from the Company to EIS, which notices shall set forth a closing date; on
each such closing date, (x) EIS shall fund the amount requested, as provided
herein, and (y) the Company shall cause to be delivered to EIS a certificate or
certificates in respect thereof and a confirmation that the conditions described
in clause (iii) above have been satisfied and the Company shall furnish such
documents and instruments that EIS shall reasonably request, including updates
of the documents referred to in clauses 1(d)(ii)(I) and 1(d)(iii) above as well
as a certification that the representations in Section 2 hereof are, as of such
date, true and correct in all material respects.
The Company presently has outstanding a class of preferred
stock captioned Series L Preferred Stock (the "SERIES L PREFERRED STOCK"). At
such time, if any, during the term of the Note that the Series L Preferred Stock
has been redeemed, converted or otherwise paid in full (and EIS is otherwise
satisfied that the holder(s) thereof do not have any right of seniority over the
Series B Preferred Stock, as contemplated to be issued hereunder), then, in such
event, upon at least 10 business days' written request of the Company, the Note
shall be exchanged for shares of Series B Preferred Stock, as follows. In such
event, the Note shall be marked canceled and returned to the Company,
simultaneously with the delivery of shares of Series B Preferred Stock to EIS by
the Company; the initial number of shares shall be equal to aggregate amount
funded under the Note and accrued and unpaid interest thereon, divided by
$1,000. Thereafter, additional shares of Preferred Stock (having up to a maximum
aggregate Original Issue Price, including those previously issued, of $12.015
million) shall be issued, at the request of the Company, as follows:
(i) Each purchase and sale of shares shall be made at
such time that Newco's board of directors shall have determined that
funding is required under the JDOA, in accordance with and as permitted
by the terms thereof, and Newco shall have provided written notice
thereof to EIS and to the Company; the proceeds of the Series B
Preferred Stock shall be used solely to satisfy the Company's
obligation to provide such funding;
4
<PAGE>
(ii) The price per share shall be U.S.$1,000.00, and
shares shall be issued only in 250-share or greater increments;
(iii) A condition to each such purchase shall be (A)
that such purchase shall occur during the Development Period (as such
term is defined in the JDOA) and (B) that there is no material breach
or default by the Company hereunder or under the JDOA or the Funding
Agreement and the representations herein shall be true and correct in
all material respects as of the date made and as of the proposed
funding date (updated as to SEC Filings and similar matters) and (c)
all appropriate and applicable regulatory approvals shall have been
obtained; and
(iv) Purchases and sales of shares of Series B
Preferred Stock shall be made upon at least 10 days' written notice
from the Company to EIS, which notices shall set forth a closing date;
on each such closing date, (x) EIS shall fund the amount required to
purchase such shares, as provided herein, and (y) the Company shall
cause to be delivered to EIS a certificate or certificates in respect
thereof and a confirmation that the conditions described in clause
(iii) above have been satisfied and the Company shall furnish such
documents and instruments that EIS shall reasonably request, including
updates of the documents referred to in clauses 1(d)(ii)(I) and
1(d)(iii) above as well as a certification that the representations in
Section 2 hereof are, as of such date, true and correct in all material
respects.
(f) EXEMPTION FROM REGISTRATION. The Securities and any
underlying shares of Common Stock will be issued under an exemption or
exemptions from registration under the Securities Act of 1933, as amended (the
"SECURITIES ACT"). Accordingly, the certificates evidencing the Series A
Preferred Stock, the Series B Preferred Stock, the Common Stock, the Warrants
and any shares of Common Stock or other securities issuable upon the exercise,
conversion or exchange of any of the Securities shall, upon issuance, contain a
legend, substantially in the form as follows:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS AND NO INTEREST MAY BE SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF UNLESS THERE IS AN EFFECTIVE
REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE
SECURITIES LAWS OR THIS CORPORATION RECEIVES AN OPINION OF
COUNSEL FOR THE HOLDER OF THESE SECURITIES SATISFACTORY TO
THIS CORPORATION THAT REGISTRATION IS NOT REQUIRED UNDER SUCH
ACT OR APPLICABLE STATE SECURITIES LAWS.
THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
IS ALSO SUBJECT TO THE
5
<PAGE>
RESTRICTIONS CONTAINED IN THAT CERTAIN SECURITIES PURCHASE
AGREEMENT, DATED AS OF JANUARY 7th, 2000, BY AND BETWEEN
RIBOZYME PHARMACEUTICALS, INC. AND ELAN INTERNATIONAL
SERVICES, LTD.
SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The
Company hereby represents and warrants to EIS, as of each Closing Date, as
follows:
(a) ORGANIZATION. The Company is a corporation duly organized,
and validly existing under the laws of the state of Delaware and has all
requisite corporate power and authority to own and lease its properties, to
carry on its business as presently conducted and as proposed to be conducted and
to consummate the transactions contemplated hereby. The Company is duly
qualified as a foreign corporation and in good standing to do business in each
jurisdiction in which the nature of the business conducted or the property owned
by it requires such qualification, except where the failure to be so qualified
would not, individually or in the aggregate, have a material adverse effect on
the business, assets, liabilities (contingent or otherwise), operations,
condition (financial or otherwise), or prospects of the Company (a "COMPANY
MATERIAL ADVERSE EFFECT").
(b) CAPITALIZATION. As of the Closing Date, the Company has
reserved a sufficient number of shares of Common Stock (i) for issuance upon
conversion of the Series A Preferred Stock and the Series B Preferred Stock
being purchased hereunder by EIS (including dividends thereon), and (ii) for
issuance upon exercise of the Warrants. The Securities, when issued against
payment therefor in accordance with this Agreement, will be duly and validly
issued, fully paid and nonassessable, and will not be issued in violation of any
preemptive or similar rights. The shares of Common Stock underlying the Series A
Preferred Stock, the Series B Preferred Stock and the Warrants (the "UNDERLYING
SHARES"), when issued upon conversion or exercise in accordance with the terms
thereof, will be duly and validly issued, fully paid and nonassessable, and will
not be issued in violation of any preemptive or similar rights.
(c) AUTHORIZATION OF TRANSACTION DOCUMENTS. The Company has
full corporate power and authority to execute and deliver this Agreement and
each of the other Transaction Documents to which it is a party, and to perform
its obligations hereunder and thereunder. The execution, delivery and
performance by the Company of this Agreement and each of the other Transaction
Documents to which it is a party, including the issuance and sale of the
Securities, have been duly authorized by all requisite corporate action by the
Company and, when executed and delivered by the Company, this Agreement and each
of the other Transaction Documents to which it is a party will be the valid and
binding obligations of the Company, enforceable against the Company in
accordance with their respective terms.
(d) NO VIOLATION. The execution, delivery and performance by
the Company of this Agreement and each other Transaction Document to which it is
a party, including the issuance and sale of the Securities, and compliance with
the provisions hereof and thereof by the Company, does not conflict with or
constitute or result in a breach of or default under (or an event which with
notice or passage of time or both would constitute a default) or give rise to
any right of termination, cancellation or acceleration under (i) the Certificate
of Incorporation, as
6
<PAGE>
amended, or by-laws, of the Company, (ii) applicable law, statute, rule or
regulation, or any ruling, writ, injunction, order, judgment or decree of any
court, arbitrator, administrative agency or other governmental body applicable
to the Company or any of its properties or assets, or (iii) any material
contract or agreement affecting the Company, including any contract filed or
required by applicable law to be filed as an exhibit to the Company's Annual
Report on Form 10-K for the year ended December 31, 1998 (the "1998 FORM 10-K")
or any subsequent interim quarterly report, except where such breach, default,
termination, cancellation or acceleration would not, individually or in the
aggregate, have a Company Material Adverse Effect
(e) APPROVALS. Except as set forth on SCHEDULE 2(E), no
permit, authorization, consent, approval, or order of or by, or any notification
of or filing with, any person or entity (governmental or otherwise) is required
in connection with the execution, delivery or performance of this Agreement or
the Transaction Documents, including the issuance and sale of the Securities, by
the Company.
(f) SEC FILINGS. The Company has timely filed with the
Securities and Exchange Commission (the "SEC") all forms, reports, schedules,
statements, exhibits and other documents (collectively, the "SEC FILINGS")
required to be filed by the Company on or before the date hereof. At the time
filed, the SEC Filings, including without limitation, any financial statements,
exhibits and schedules included therein or documents incorporated therein by
reference (i) did not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading and (ii) complied in all material respects with the
applicable requirements of the Securities Act or the Securities Exchange Act of
1934, as amended (the "EXCHANGE ACT"), as the case may be.
(g) FINANCIAL STATEMENTS. The audited balance sheet of the
Company at December 31, 1998 and 1997 and unaudited balance sheet September 30,
1999, together with the related statements of operations, stockholders' equity
(deficit) and cash flows for each of the two years ended December 31, 1998 and
1997 and the nine months ended September 30, 1999, together with the reports and
opinions thereon of Ernst & Young, contained in the Company's 1998 and 1997 Form
10-K, comply as to form in all material respects with applicable accounting
requirements and the published rules and regulation of the SEC with respect
thereto, and fairly present, in all material respects, the financial position of
the Company and the results of its operations and its cash flows at such dates
and for the years then ended and were prepared in conformity in all material
respects with generally accepted accounting principles applied on a consistent
basis.
(h) LITIGATION. There is no legal, administrative, arbitration
or other action or proceeding or governmental or investigation pending, or to
the Company's knowledge, threatened against the Company, or any director,
officer or employee of the Company that challenges the validity or performance
of this Agreement or the other Transaction Documents to which the Company is a
party.
7
<PAGE>
(i) ABSENCE OF CERTAIN EVENTS. Since September 30, 1999,
except as contemplated by the Transaction Documents or as set forth on SCHEDULE
2(I) hereto, (A) the Company has not (i) made, paid or declared any dividend or
distribution to any equity holder (in such capacity) or redeemed any of its
capital stock, (ii) varied its business plan or practices, in any material
respect, from past practices, (iii) entered into any financing, joint venture,
license or similar arrangement that would limit or restrict its ability to
perform its obligations hereunder and under each of the other Transaction
Documents to which it is a party, or (iv) suffered or permitted to be incurred
any liability or obligation or any lien or encumbrance against any of its
properties or assets that would limit or restrict its ability to perform its
obligations hereunder and under each of the other Transaction Documents to which
it is a party, and (B) there has not been any change or development which has
had, or in the Company's reasonable judgement is likely to have, a Company
Material Adverse Effect except as disclosed on Schedule 2 (i) hereto.
(j) DISCLOSURE. The representations and warranties set forth
herein and in the other Transaction Documents, when viewed collectively, do not
contain any untrue statement of a material fact or omit to state any material
fact necessary to make the statements contained herein not misleading in light
of the circumstances in which they were made.
(k) BROKERS OR FINDERS. There have been no investment bankers,
brokers or finders used by the Company in connection with the transactions
contemplated by the Transaction Documents and no persons or entities are
entitled to a fee or compensation in respect thereof.
SECTION 3. REPRESENTATION AND WARRANTIES OF EIS. EIS hereby
represents and warrants to the Company, as of each Closing Date, as follows:
(a) ORGANIZATION. EIS is an exempted company duly organized,
validly existing and in good standing under the laws of Bermuda and has all
requisite corporate power and authority to own and lease its properties, to
carry on its business as presently conducted and as proposed to be conducted and
to consummate the transactions contemplated hereby. EIS is duly qualified as a
foreign corporation and in good standing to do business in each jurisdiction in
which the nature of the business conducted or the property owned by it requires
such qualification, except where the failure to be so qualified would not,
individually or in the aggregate, have a material adverse effect on the
business, assets, liabilities (contingent or otherwise), operations, condition
(financial or otherwise), or prospects of EIS (an "EIS MATERIAL ADVERSE
EFFECT").
(b) AUTHORIZATION OF TRANSACTION DOCUMENTS. EIS has full
corporate power and authority to execute and deliver this Agreement and each of
the other Transaction Documents to which it is a party, and to perform its
obligations hereunder and thereunder. The execution, delivery, and performance
by EIS of this Agreement and each other Transaction Document to which it is a
party, including the purchase and acceptance of the Securities, have been duly
authorized by all requisite corporate action by EIS and, when executed and
delivered by EIS, this Agreement and each of the other Transaction Documents to
which it is a party, will be the valid and binding obligations of EIS,
enforceable against it in accordance with their respective terms.
8
<PAGE>
(c) NO VIOLATION. The execution, delivery and performance by
EIS of this Agreement and each other Transaction Document to which it is a
party, including the purchase and acceptance of the Securities, and compliance
with provisions hereof and thereof by EIS, will not conflict with or constitute
or result in a breach of or default under (or an event which with notice or
passage of time or both would constitute a default) or give rise to any right of
termination, cancellation or acceleration under (i) the by-laws of EIS, (ii)
applicable law, statute, rule or regulation, or any ruling, writ, injunction,
order, judgment or decree of any court, arbitrator, administrative agency or
other governmental body applicable to EIS or any of its properties or assets, or
(iii) any material contract to which EIS is a party, except where such breach,
default, termination, cancellation or acceleration would not, individually or in
the aggregate, have an EIS Material Adverse Effect.
(d) APPROVALS. Except for consent required under the Mergers
and Takeovers (Control) Acts 1978-1996 (Ireland), no material permit,
authorization, consent, approval or order of or by, or any notification of or
filing with, any person or entity (governmental or otherwise) is required in
connection with the execution, delivery or performance of this Agreement or the
Transaction Documents by EIS.
(e) INVESTMENT REPRESENTATIONS.
(i) EIS is sophisticated in transactions of this type
and capable of evaluating the merits and risks of the transactions
described herein and in the other Transaction Documents to which it is
a party, and has the capacity to protect its own interests. EIS has not
been formed solely for the purpose of entering into the transactions
described herein and therein and is acquiring the Securities (and the
Underlying Shares) for investment for its own account, not as a nominee
or agent, and not with the view to, or for resale, distribution or
fractionalization thereof, in whole or in part, and no other person
(other than Elan) has a direct or indirect interest, beneficial or
otherwise in the Securities (or the Underlying Shares); provided,
however, that EIS shall be permitted to convert or exchange such
Securities in accordance with their terms.
(ii) EIS has not and does not intend to enter into
any contract, undertaking, agreement or arrangement with any person or
entity to sell, transfer or pledge the Securities (or the Underlying
Shares).
(iii) EIS acknowledges its understanding that the
private placement and sale of the Securities (and the Underlying
Shares) is exempt from registration under the Securities Act. In
furtherance thereof, EIS represents and warrants that it is an
"accredited investor" as that term is defined in the regulations under
the Securities Act, has the financial ability to bear the economic risk
of its investment, has adequate means for providing for its current
needs and personal contingencies and has no need for liquidity with
respect to its investment in the Company.
(iv) EIS agrees that it shall not sell or otherwise
transfer any of the Securities (or the Underlying Shares) without
registration under the Securities Act or pursuant to an opinion of
counsel reasonably satisfactory to the Company that an
9
<PAGE>
exemption from registration is available, and fully understands and
agrees that it must bear the total economic risk of its purchase for an
indefinite period of time because, among other reasons, none of the
Securities (or the Underlying Shares) have been registered under the
Securities Act or under the securities laws of any applicable state or
other jurisdiction and, therefore, cannot be resold, pledged, assigned
or otherwise disposed of unless subsequently registered under the
Securities Act and under the applicable securities laws of such states
or jurisdictions or an exemption from such registration is available.
EIS understands that the Company is under no obligation to register the
Securities (or the Underlying Shares) on its behalf with the exception
of certain registration rights with respect to certain of the
Securities (and the Underlying Shares), as provided in the Company
Registration Rights Agreement. EIS understands the lack of liquidity
and restrictions on transfer of the Securities (and the Underlying
Shares) and that this investment is suitable only for a person or
entity of adequate financial means that has no need for liquidity of
this investment and that can afford a total loss of its investment.
(f) LITIGATION. There is no legal, administrative, arbitration
or other action or proceeding or governmental investigation pending, or to EIS's
knowledge threatened, against EIS that challenges the validity or performance of
this Agreement or the other Transaction Documents to which EIS is a party.
(g) BROKERS OR FINDERS. There have been no investment bankers,
brokers or finders used by EIS in connection with the transactions contemplated
by the Transaction Documents and no persons or entities are entitled to a fee or
compensation in respect thereof.
SECTION 4. COVENANTS OF THE PARTIES.
(a) CERTAIN COVENANTS. From and after the Closing Date and
until the earlier to occur of the exercise or expiration of the EIS Exchange
Right (as such term is defined in Section 5(c) hereof), the Company shall not
without the prior written consent of EIS: (i) sell, transfer, encumber, pledge
or otherwise affect, in any respect, (A) any Newco Preferred Shares owned by the
Company, including, without limitation, those Newco Preferred Shares
transferable to EIS upon exercise by EIS of the EIS Exchange Right, or (B)
affect, in any respect, the Company's ability to permit EIS to exercise the EIS
Exchange Right in full, as provided herein or (ii) enter into any material
transaction with a director, officer or more than 20% beneficial owner of Common
Stock on other than an arm's length basis.
(b) FULLY-DILUTED STOCK OWNERSHIP. Notwithstanding any other
provision of this Agreement, in the event that EIS shall have determined that at
any time it (together with its affiliates, if applicable) holds or has the right
to receive Common Stock (or securities or rights, options or warrants
exercisable, exchangeable or convertible for or into Common Stock) representing
in the aggregate in excess of 9.9% of the Company's outstanding Common Stock on
a fully diluted basis, EIS shall have the right to convert the Series A
Preferred Stock, the Note, the Series B Preferred Stock, and the Warrants into
other junior, non-voting securities of the Company (to be specified by EIS and
reasonably agreed to by the Company and not having superior rights to the rights
attendant to the Common Stock) such that EIS and its affiliates will
10
<PAGE>
not directly or indirectly own more than 9.9% of the Common Stock for a period
of at least two years from the election to convert any of the Series A Preferred
Stock, the Note, Series B Preferred Stock or the Warrants. Each of the Company
and EIS shall use commercially reasonable efforts to effect such transactions
and any required subsequent conversions or adjustments to EIS's securities
position, on a quarterly basis, within 15 business days of the end of each of
Elan's fiscal quarters.
(c) USE OF PROCEEDS. The Company shall use the proceeds of
(i) the issuance and sale of the Series A Preferred Stock solely to fund its
initial capital contribution to and funding of Newco as described in the JDOA
and (ii) the issuance and sale of the Note and the Series B Preferred Stock
solely to fund development amounts in connection with the business of Newco,
as described in the Funding Agreement; and, in each case, for no other
purpose.
(d) CONFIDENTIALITY; NON-DISCLOSURE.
(i) Subject to clauses (ii) and (iii) below, from and
after the date hereof, neither the Company nor EIS (nor their
respective affiliates) shall disclose to any person or entity this
Agreement or the other Transaction Documents or the contents thereof or
the parties thereto, except that such parties may make such disclosure
(x) to their directors, officers, employees and advisors, so long as
they shall have advised such persons of the obligation of
confidentiality herein and for whose breach or default the disclosing
party shall be responsible, or (y) as required by applicable law, rule,
regulation or judicial or administrative process, provided that the
disclosing party uses reasonable efforts to obtain an order or ruling
protecting the confidentiality of confidential information of the other
party contained herein or therein. The parties shall be entitled to
seek injunctive or other equitable relief in respect of any breach or
threatened breach of the foregoing covenant without the requirement of
posting a bond or other collateral.
(ii) Prior to issuing any press release or public
disclosure in respect of this Agreement or the transactions
contemplated hereby, the party proposing such issuance, shall obtain
the consent of the other party to the contents thereof, which consent
shall not be unreasonably withheld or delayed; it being understood that
if such second party shall not have responded to such consent request
within two business days, such consent shall be deemed given.
(e) FURTHER ASSURANCES. From and after the date hereof, each
of the parties hereto agree to do or cause to be done such further acts and
things and deliver or cause to be delivered to each other such additional
assignments, agreements, powers and instruments, as each may reasonably require
or deem advisable to carry into effect the purposes of this Agreement and the
other Transaction Documents.
SECTION 5. CERTAIN RIGHTS OF EIS. (a) PREEMPTIVE RIGHT. Until
the fourth anniversary of the Initial Closing Date, EIS shall have the right
(but not the obligation) to participate in any equity, warrant, or convertible
or exchangeable for equity financing consummated by the Company, in order for
EIS to maintain its PRO RATA interest in the Company, based on the number of
shares of Common Stock owned by EIS and its affiliates, assuring the conversion
or exercise of all Securities and the actual number of shares of Common Stock
11
<PAGE>
outstanding on the date such financing is consummated; provided, that such right
shall not apply to any public offering under the Securities Act, offering under
an option plan, or asset or company acquisition paid for, in whole or in part,
in shares of Common Stock. Such right shall be exercised by EIS within 10 days
of receipt of notice of such financing from the Company, which notice shall be
provided by the Company at least 15 days prior to such financing. Such
participation by EIS shall be on the same terms and conditions offered to any
other potential investor in such offering.
(b) COMPANY BOARD OF DIRECTORS. For so long as (i) EIS
and/or its affiliates or subsidiaries collectively own Securities that
represent ownership of at least 10% of the Common Stock (or Securities
convertible, exchangeable or exercisable for or into the Common Stock) on a
fully diluted basis (assuming the exercise, conversion or exchange by EIS and
its affiliates but no other Common Stock equivalents), or (ii) until the date
that is five years after the date hereof, EIS shall be entitled to nominate
one director (the "EIS DIRECTOR") for election to the Company's Board. In
connection with the foregoing, the Company will take all necessary and/or
appropriate steps to effect such appointment, including the inclusion of the
designated EIS Director on the recommended slate of directors presented at
any regular or special meeting of the stockholders of the Company at which
directors of the Company are to be elected. Prior to such election, the
designated EIS Director shall be entitled to be an observer at the meetings
of the Company's board of directors.
(c) CONVERSION AND EXCHANGE RIGHTS; ETC. (i) The Certificate
of Designations sets forth certain rights of the holders of shares of Series A
Preferred Stock to convert such shares of preferred stock into newly issued
shares of Common Stock, or to exchange such shares of Series A Preferred Stock,
subject to the provisions in Section 5 of the Certificate of Designations, for
certain shares of Newco Stock (the "EIS EXCHANGE RIGHT"), both on the terms and
conditions set forth therein.
(ii) In the event that all or any portion of the
issued and outstanding shares of Series A Preferred Stock are converted into
shares of Common Stock on or prior to the last day permitted to exercise the EIS
Exchange Right, as permitted by the Certificate of Designations, as a result of
a merger, consolidation or similar transaction involving the Company (each, a
"MERGER CONVERSION"), then, in such event, the EIS Exchange Right shall not be
terminated, as otherwise provided in the Certificate of Designations, but
rather, EIS and the holders of the Series A Preferred Stock shall retain the EIS
Exchange Right until the Exchange Right Termination Date (as defined in the
Certificate of Designations); provided, that the consideration payable to the
Company to exercise the EIS Exchange Right shall be the shares of Common Stock
issued to the holders of the Series A Preferred Stock in connection with a
Merger Conversion rather than the shares of Series A Preferred Stock as
originally provided for in the Certificate of Designations.
SECTION 6. [intentionally omitted]
SECTION 7. SURVIVAL AND INDEMNIFICATION. (a) SURVIVAL. The
representations and warranties of the Company and EIS contained herein and the
other Transaction Documents shall survive for a period of 24 months from and
after the date hereof.
12
<PAGE>
(b) INDEMNIFICATION. In addition to all rights and remedies
available to the parties hereto at law or in equity, the Company (in such
capacity, "INDEMNIFYING PARTY") shall indemnify EIS, its stockholders, officers,
directors and assigns, their affiliates, and its affiliates' stockholders,
officers, directors, employees, agents, representatives, successors and assigns
(collectively, the "INDEMNIFIED PERSON"), and save and hold each Indemnified
Person harmless from and against and pay on behalf of or reimburse each such
Indemnified Person, as and when incurred, for any and all loss, liability,
demand, claim, action, cause of action, cost, damage, deficiency, tax, penalty,
fine or expense, whether or not arising out of any claims by or on behalf of
such Indemnified Person or any third party, including interest, penalties,
reasonable attorneys' fees and expenses and all amounts paid in investigation,
defense or settlement of any of the foregoing (collectively, "LOSSES"), that any
such Indemnified Person may suffer, sustain incur or become subject to, as a
result of, in connection with, relating or incidental to or by virtue of:
(i) any misrepresentation or breach of warranty on
the part of the Indemnifying Party in the case of the Company under
Section 2 of this Agreement or in the case of EIS under Section 3 of
this Agreement or, in each case, under any of the other Transaction
Documents; or
(ii) any nonfulfillment, default or breach of any
covenant or agreement on the part of the Indemnifying Party under
Section 4 of this Agreement or any of the other Transaction Documents.
(c) MAXIMUM RECOVERY. Notwithstanding anything in this
Agreement to the contrary, in no event shall the Indemnifying Parties be liable,
in the case of the Company, for indemnification under this Section 7 in an
amount in excess of the aggregate of the purchase price paid for the Securities,
including the amounts advanced and not repaid under the Note, or, in the case of
EIS, for indemnification hereunder in an amount in excess the Company's costs
and expenses incurred in connection with the transactions contemplated hereby.
No Indemnified Person shall assert any such claim unless Losses in respect
thereof incurred by any Indemnified Person, when aggregated with all previous
Losses hereunder, equal or exceed U.S.$50,000, but at such time that an
Indemnified Person is entitled to assert a claim, such claim shall include all
Losses covered by this Section 7.
(d) EXCEPTION. Notwithstanding the foregoing, upon judicial
determination that is final and no longer appealable, that the act or omission
giving rise to the indemnification set forth above resulted primarily out of or
was based primarily upon the Indemnified Person's negligence (unless such
Indemnified Person's negligence was based upon the Indemnified Person's reliance
in good faith upon any of the representations, warranties, covenants or promises
made by the Indemnifying Party herein) the Indemnifying Party shall not be
responsible for any Losses sought to be indemnified in connection therewith, and
the Indemnifying Party shall be entitled to recover from the Indemnified Person
all amounts previously paid in full or partial satisfaction of such indemnity,
together with all costs and expenses (including reasonable attorneys fees) of
the Indemnifying Party reasonably incurred in connection with the Indemnified
Persons claim for indemnity, together with interest at the rate per annum
publicly announced by
13
<PAGE>
Morgan Guaranty Trust Company as its prime rate from the time of payment of such
amounts to the Indemnified Person until repayment to the Indemnifying Party.
(e) INVESTIGATION. All indemnification rights hereunder shall
survive the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby, to the extent provided in Section 7(g) below,
irrespective of any investigation, inquiry or examination made for or on behalf
of, or any knowledge of the Indemnified Person or the acceptance of any
certificate or opinion.
(f) CONTRIBUTION. If the indemnity provided for in this
Section 7 shall be, in whole or in part, unavailable to any Indemnified Person,
due to Section 7(b) being declared unenforceable by a court of competent
jurisdiction based upon reasons of public policy, so that Section 7(b) shall be
insufficient to hold each such Indemnified Person harmless from Losses which
would otherwise be indemnified hereunder, then the Indemnifying Party and the
Indemnified Person shall each contribute to the amount paid or payable for such
Loss in such proportion as is appropriate to reflect not only the relative
benefits received by the Indemnifying Party on the one hand and the Indemnified
Person on the other, but also the relative fault of the Indemnifying Party and
be in addition to any liability that the Indemnifying Party may otherwise have.
The indemnity, contribution and expense reimbursement obligations that the
Indemnifying Party has under this Section 7 shall survive the expiration of the
Transaction Documents. The parties hereto further agree that the indemnification
and reimbursement commitments set forth in this Agreement shall apply whether or
not the Indemnified Person is a formal party to any such lawsuit, claims or
other proceedings.
(g) LIMITATION. No claim shall be brought by an Indemnified
Person in respect of any misrepresentation or breach of warranty under this
Agreement after 24 months from the date hereof; and any claim for
nonfulfillment, default or breach of any covenant or any misrepresentation shall
be brought within one year of the date of that such Indemnified Person became
aware or should have become aware of the nonfulfillment, default or breach.
Except as set forth in the previous sentence and in Section 7(c) above, this
Section 7 is not intended to limit the rights or remedies otherwise available to
any party hereto with respect to this Agreement or the Transaction Documents.
SECTION 8. NOTICES. All notices, demands and requests of any
kind to be delivered to any party in connection with this Agreement shall be in
writing and shall be deemed to have been duly given if personally or hand
delivered or if sent by an internationally-recognized overnight delivery or by
registered or certified mail, return receipt requested and postage prepaid, or
by facsimile transmission addressed as follows:
(i) if to the Company, to:
Ribozyme Pharmaceuticals, Inc.
2950 Wilderness Place
Boulder, Colorado 80301
Attention: Chief Executive Officer
Facsimile: 303-449-6995
14
<PAGE>
with a copy to:
Rothgerber Johnson & Lyons LLC
1200 17th Street, Suite 3000
Denver, Colorado 80202
Attention: Woody Davis
Facsimile: (303) 623-9222
(ii) if to EIS, to:
Elan International Services, Ltd.
102 St. James Court
Flatts, Smiths Parish
Bermuda, FL 04
Attention: Director
Facsimile: 441-292-2224
with a copy to:
Brock Silverstein LLC
800 Third Avenue, 21st Floor
New York, New York 10022
Attention: David Robbins
Facsimile: 212-371-5500
or to such other address as the party to whom notice is to be given may have
furnished to the other party hereto in writing in accordance with provisions of
this Section 8. Any such notice or communication shall be deemed to have been
effectively given (i) in the case of personal or hand delivery, on the date of
such delivery, (ii) in the case of an internationally-recognized overnight
delivery service, on the second business day after the date when sent, (iii) in
the case of mailing, on the fifth business day following that day on which the
piece of mail containing such communication is posted, and (iv) in the case of
facsimile transmission, on the date of telephone confirmation of receipt.
SECTION 9. ENTIRE AGREEMENT. This Agreement and the other
Transaction Documents contain the entire understanding of the parties with
respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings among the parties with respect thereto.
SECTION 10. AMENDMENTS. This Agreement may not be modified or
amended, or any of the provisions hereof waived, except by written agreement of
the Company and EIS dated after the date hereof.
SECTION 11. COUNTERPARTS AND FACSIMILE. The Transaction
Documents may be executed in any number of counterparts, and each such
counterpart hereof shall be deemed to be
15
<PAGE>
an original instrument, but all such counterparts together shall constitute
one agreement. Each of the Transaction Documents may be signed and delivered
to the other party by facsimile transmission; such transmission shall be
deemed a valid signature.
SECTION 12. HEADINGS. The section and paragraph headings
contained in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of the Agreement.
SECTION 13. GOVERNING LAW. This Agreement shall be governed by
and construed in accordance with the internal laws of the State of Delaware,
without giving effect to principles of conflicts of laws. Any dispute hereunder
may be adjudicated, on a non-exclusive basis, in any federal or state court
sitting in the County, City and State of New York.
SECTION 14. EXPENSES. Each of the parties shall be responsible
for its own costs and expenses incurred in connection with the transactions
contemplated hereby and by the other Transaction Documents.
SECTION 15. ASSIGNMENTS AND TRANSFERS. This Agreement and all
of the provisions hereof shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted assigns. This
Agreement, the shares of Series A Preferred Stock, the Series B Preferred Stock
and Common Stock being purchased hereunder by EIS, the Warrants, the Note and
the shares of Common Stock underlying the Series A Preferred Stock, the Series B
Preferred Stock, the Note and the Warrants may be transferred by EIS to its
affiliates and subsidiaries, as well as any special purpose financing or similar
vehicle established by EIS or its affiliates; provided, however, that EIS shall
remain liable for its obligations hereunder after any such assignment. Other
than as set forth above, no party shall transfer or assign this Agreement or
such securities without the prior written consent of the other party, which will
not be unreasonably withheld.
SECTION 16. SEVERABILITY. In case any provision of this
Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not be in any way affected or
impaired thereby.
16
<PAGE>
IN WITNESS WHEREOF, each of the undersigned has duly executed
this Agreement as of the date first written above.
RIBOZYME PHARMACEUTICALS, INC.
By:
----------------------------------
Name:
Title:
ELAN INTERNATIONAL SERVICES, LTD.
By:
----------------------------------
Name:
Title:
